Personalized cancer medicine--advances and socio-economic challenges.
作者： David B. Jackson , Anil K. Sood
DOI: 10.1038/NRCLINONC.2011.151
关键词:
摘要: The use of therapy that is truly targeted to the needs and biological requirements an individual patient aim for many in oncology field. Jackson Sood discuss implications therapies on patients health-care system methods might be used maximize efficiency, cost effectiveness survival.
nature.com
sci-hub.se 参考文章(59)
Keiran S M Smalley, PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma. Current opinion in investigational drugs. ,vol. 11, pp. 699- 706 ,(2010)
Edward C. Norton, Sally C. Stearns, Health Care Expenditures Springer, Dordrecht. pp. 631- 645 ,(2009) , 10.1007/978-1-4020-8356-3_28
Francis Adams, Hippocrates, Emerson Crosby Kelly, The genuine works of Hippocrates ,(1849)
Bruce A. Chabner, Thomas G. Roberts, Chemotherapy and the war on cancer Nature Reviews Cancer. ,vol. 5, pp. 65- 72 ,(2005) , 10.1038/NRC1529
S. Kopetz, J. Desai, E. Chan, J. R. Hecht, P. J. O'Dwyer, R. J. Lee, K. B. Nolop, L. Saltz, PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. Journal of Clinical Oncology. ,vol. 28, pp. 3534- 3534 ,(2010) , 10.1200/JCO.2010.28.15_SUPPL.3534
Edward S Kim, Roy S Herbst, Ignacio I Wistuba, J Jack Lee, George R Blumenschein Jr, Anne Tsao, David J Stewart, Marshall E Hicks, Jeremy Erasmus Jr, Sanjay Gupta, Christine M Alden, Suyu Liu, Ximing Tang, Fadlo R Khuri, Hai T Tran, Bruce E Johnson, John V Heymach, Li Mao, Frank Fossella, Merrill S Kies, Vassiliki Papadimitrakopoulou, Suzanne E Davis, Scott M Lippman, Waun K Hong, None, The BATTLE Trial: Personalizing Therapy for Lung Cancer Cancer Discovery. ,vol. 1, pp. 44- 53 ,(2011) , 10.1158/2159-8274.CD-10-0010
J. Glaspy, A. Brufsky, I. Bondarenko, O. Lipatov, E.A. Perez, S. Chan, X. Zhou, S.C. Phan, N. Robert, V. Dieras, 5016 Efficacy in patient subgroups in RIBBON-1, a randomized, double-blind, Phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC) Ejc Supplements. ,vol. 7, pp. 265- ,(2009) , 10.1016/S1359-6349(09)70908-5
David B. Jackson, Clinical and economic impact of the nonresponder phenomenon--implications for systems based discovery. Drug Discovery Today. ,vol. 14, pp. 380- 385 ,(2009) , 10.1016/J.DRUDIS.2009.01.006
J. Couzin-Frankel, Y. Ogale, Once on 'Fast Track,' Avastin Now Derailed Science. ,vol. 333, pp. 143- 144 ,(2011) , 10.1126/SCIENCE.333.6039.143